Curis - - 500 Beiträge pro Seite
eröffnet am 07.11.00 19:47:14 von
neuester Beitrag 27.05.03 22:29:09 von
neuester Beitrag 27.05.03 22:29:09 von
Beiträge: 46
ID: 293.391
ID: 293.391
Aufrufe heute: 0
Gesamt: 5.734
Gesamt: 5.734
Aktive User: 0
ISIN: US2312693094 · WKN: A3ETJD
15,100
EUR
0,00 %
0,000 EUR
Letzter Kurs 08:57:08 Lang & Schwarz
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,4000 | +49,07 | |
| 1,1600 | +40,52 | |
| 4,6900 | +28,49 | |
| 5,1200 | +28,00 | |
| 1,3670 | +25,30 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 7,9000 | -12,22 | |
| 1,3800 | -20,80 | |
| 0,6700 | -26,58 | |
| 2,1300 | -34,41 | |
| 3,1600 | -38,64 |
Feedback
völlig unterbewertet steht Curis(ehemals Creative Biomoleculs)
bei 14 Euro.
Die Productpipeline von Curis kann sich durchaus sehen lassen.
Hier hat man die Chanche,bei einer Erfolgsstorie von Anfang an dabei zu sein.
Also,warum nicht mal einen unbekannteren Biotec ins Depot legen,der nicht die
Aufmerksamkeit wie Vertex oder Millennium geniesst.
News werden mit Sicherheit kommen.
MfG Lima
bei 14 Euro.
Die Productpipeline von Curis kann sich durchaus sehen lassen.
Hier hat man die Chanche,bei einer Erfolgsstorie von Anfang an dabei zu sein.
Also,warum nicht mal einen unbekannteren Biotec ins Depot legen,der nicht die
Aufmerksamkeit wie Vertex oder Millennium geniesst.
News werden mit Sicherheit kommen.
MfG Lima
sehr schön - plus 34 %
Curis Reports Third Quarter Fiscal 2000 Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Nov. 14, 2000--Curis, Inc. (NASDAQ:CRIS) today reported the results of its operations for the three- and nine-month periods ended September 30, 2000. These results include combined results of the three companies merged into Curis as described below.
On July 31, 2000, Creative BioMolecules, Inc. (formerly Nasdaq:CBMI), Ontogeny, Inc., and Reprogenesis, Inc., merged with and into Curis, Inc. On that date, Curis, as the surviving company of the merger, assumed the rights and obligations of Creative, Ontogeny and Reprogenesis. Immediately after the merger, Curis was owned approximately 43 percent by the former stockholders of Creative, 38 percent by the former stockholders of Ontogeny and 19 percent by the former stockholders of Reprogenesis. Consequently, for accounting purposes, Curis is deemed to be the successor to Creative, and the historical financial statements of Creative have become the historical financial statements of Curis.
Excluding one-time costs and expenses, amortization of intangibles and stock-based compensation, total net loss for the three months ended September 30, 2000 would have been $7,675,000, or $.36 per share. Financial results for the three-month period ended September 30, 2000 included a number of significant, non-recurring, non-cash charges and other merger-related cash expenses incurred in connection with the merger and the formation of Curis on July 31, 2000. These include costs and expenses as follows: a one-time non-cash charge of $294,800,000 resulting from the allocated portion of the purchase price of Ontogeny and Reprogenesis identified under the accounting rules as in-process research and development; stock-based compensation of $9,356,000; amortization of intangible assets of $8,529,000; severance paid to former executive officers and former employees of $1,955,000; and a loss on the disposition of assets of $554,000.
Operating expenses for the third quarter of 2000 include all costs incurred by Curis for the period from August 1, 2000 to September 30, 2000 and all costs incurred by Creative BioMolecules for the month of July, 2000. Excluding the one-time costs and expenses, amortization of intangibles and stock-based compensation, total operating expenses for the three months ended September 30, 2000 would have been $8,142,000.
Curis` cash and investment balance on September 30, 2000 was $44,169,000, which included restricted securities of $4,989,000. The Company had 26,015,824 shares outstanding on September 30, 2000.
Primarily as a result of merger-related expenses, Curis reported a net loss of $322,869,000 or $15.19 per share, for the three-month period ended September 30, 2000, compared with a net loss of $2,995,000, or $0.28 per share, for the three-month period ended September 30, 1999. Per share amounts are on both a basic and diluted basis.
Total revenues for the three-month period ended September 30, 2000 were $66,000 as compared to $824,000 for the same period in 1999. The decrease in revenues was primarily the result of the termination of a research agreement with Biogen, Inc. in 1999, which was partially offset by revenues earned under a National Institute of Standards and Technology (NIST) grant received in November 1999.
Total operating expenses for the three-month period ended September 30, 2000 were $323,336,000, as compared to $4,138,000 for the same period in 1999..
"The fiscal quarter ended September 30, 2000 was the first for Curis following shareholder approval of the merger of Creative BioMolecules, Ontogeny, and Reprogenesis," said Doros Platika, M.D., president and chief executive officer of Curis. "It has been a busy and exciting start to a new company that is building a leadership presence in regenerative medicine.
"The quarter was marked by several research findings based upon the core developmental biology and functional genomics technologies driving the discovery of innovative therapies at Curis," said Dr. Platika. "These included a demonstration that treatment with the Sonic Hedgehog protein restored nerve function to normal in pre-clinical models of diabetic neuropathy. Additional findings showed that the Hedgehog pathway is activated following injury to peripheral nerves in pre-clinical models and plays a key role in the nerve recovery process. These studies represent critical components in our program leading up to the introduction of a Hedgehog-based therapy into clinical testing.
"Earlier in the quarter, research published in Nature (Vol. 406, 31 August 2000) demonstrated that Curis` approach to treating basal cell carcinoma is based on fundamental genetic differences between cancer cells and normal cells," said Dr. Platika. "Our compound, CUR-61414, inhibits the biological process that leads to the uncontrolled growth seen in basal cell and certain other cancers. We expect to file an Investigational New Drug (IND) application to begin human clinical testing with this compound next year.
"On the clinical front, enrollment in our Phase III clinical trial with Chondrogel was completed in September," said Dr. Platika. "Data from this trial in children with vesicoureteral reflux is expected in late 2001. Pending evaluation of this data, we expect to submit a Biologics License Application (BLA) to the U.S. FDA in the first half of 2002, and we plan to market this product ourselves.
"In October, Curis received a second $2,000,000 grant from the National Institute of Standards and Technology (NIST) to support the development of a new class of biomaterials designed to enable minimally invasive surgical procedures," said Dr. Platika. "Such procedures would significantly reduce postoperative pain and decrease the length of hospital stays, recovery time and healthcare costs. Initial applications targeted by NIST under this grant include gastroesophogeal reflux disease and stress urinary incontinence."
Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. Curis is combining insights gained through the study of developmental biology with high-throughput screening capabilities, proteins, cells and biocompatible materials to facilitate the development of new regenerative medicine therapies. For more information, please visit the Curis web site at http://www.curis.com.
The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, regulatory approval and commercialization, the impact of competitive products, patents, patent litigation, product liability, third party reimbursement, and other risks and uncertainties associated with the biotechnology industry. For additional factors that could cause actual results to differ materially, please refer to the risk factors section of the Curis joint proxy statement/prospectus filed with the Securities and Exchange Commission on June 19, 2000.
CURIS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
Three months ended Nine months ended
September 30, September 30,
2000 1999 2000 1999
Revenues $ 65,955 $ 823,573 $ 743,813 $ 2,405,760
Operating expenses:
Research and
development 6,056,255 2,708,005 10,072,461 8,072,342
General and
administrative 4,040,568 1,317,051 6,604,422 4,078,187
Stock-based
compensation 9,356,112 -- 12,495,590 64,000
Amortization
of intangible
assets 8,529,302 112,725 8,647,473 325,705
Loss on
disposition
of fixed assets 553,912 -- 248,516 --
In-process
research &
development 294,800,000 -- 294,800,000 --
Total
operating
expenses 323,336,149 4,137,781 332,868,462 12,540,234
Net loss from
operations (323,270,194) (3,314,208) (332,124,649) (10,134,474)
Interest and
other income 580,706 366,177 1,164,252 1,617,577
Interest expense (179,747) (46,528) (265,362) (114,780)
Total other
income 400,959 319,649 898,890 1,502,797
Net loss $(322,869,235)$ (2,994,559)$(331,225,759)$ (8,631,677)
Accretion and
repurchase
costs on Series
1998/A
Preferred Stock -- -- -- (2,395,559)
Net loss
applicable
to common
stockholders $(322,869,235)$ (2,994,559)$(331,225,759)$ (11,027,236)
Basic and
diluted net
loss per
common share $ (15.19)$ (0.28)$ (22.59)$ (1.04)
Weighted
average common
shares for
basic and
diluted
net loss
computation 21,250,137 10,798,008 14,662,960 10,618,696
CURIS, INC.
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
September 30, December 31,
2000 1999
ASSETS
Cash, cash equivalents and
marketable securities $ 44,168,748 $ 21,370,585
Property and equipment, net 7,437,337 2,130,158
Intangible assets 113,737,522 5,075,914
Other assets 1,386,988 315,634
Total assets $166,730,595 $ 28,892,291
LIABILITIES AND STOCKHOLDERS`
EQUITY
Accounts payable and
accrued expenses $ 8,061,659 $ 4,113,994
Debt and capital
lease obligations 5,537,264 1,356,711
Total liabilities 13,598,923 5,470,705
Total stockholders` equity 153,131,672 23,421,586
Total liabilities and
stockholders` equity $166,730,595 $ 28,892,291
CONTACT: Curis, Inc.
William B. Boni
(617) 876-0086, ext. 6506
or
Cynthia Clayton
(617) 876-0086, ext. 6641
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Nov. 14, 2000--Curis, Inc. (NASDAQ:CRIS) today reported the results of its operations for the three- and nine-month periods ended September 30, 2000. These results include combined results of the three companies merged into Curis as described below.
On July 31, 2000, Creative BioMolecules, Inc. (formerly Nasdaq:CBMI), Ontogeny, Inc., and Reprogenesis, Inc., merged with and into Curis, Inc. On that date, Curis, as the surviving company of the merger, assumed the rights and obligations of Creative, Ontogeny and Reprogenesis. Immediately after the merger, Curis was owned approximately 43 percent by the former stockholders of Creative, 38 percent by the former stockholders of Ontogeny and 19 percent by the former stockholders of Reprogenesis. Consequently, for accounting purposes, Curis is deemed to be the successor to Creative, and the historical financial statements of Creative have become the historical financial statements of Curis.
Excluding one-time costs and expenses, amortization of intangibles and stock-based compensation, total net loss for the three months ended September 30, 2000 would have been $7,675,000, or $.36 per share. Financial results for the three-month period ended September 30, 2000 included a number of significant, non-recurring, non-cash charges and other merger-related cash expenses incurred in connection with the merger and the formation of Curis on July 31, 2000. These include costs and expenses as follows: a one-time non-cash charge of $294,800,000 resulting from the allocated portion of the purchase price of Ontogeny and Reprogenesis identified under the accounting rules as in-process research and development; stock-based compensation of $9,356,000; amortization of intangible assets of $8,529,000; severance paid to former executive officers and former employees of $1,955,000; and a loss on the disposition of assets of $554,000.
Operating expenses for the third quarter of 2000 include all costs incurred by Curis for the period from August 1, 2000 to September 30, 2000 and all costs incurred by Creative BioMolecules for the month of July, 2000. Excluding the one-time costs and expenses, amortization of intangibles and stock-based compensation, total operating expenses for the three months ended September 30, 2000 would have been $8,142,000.
Curis` cash and investment balance on September 30, 2000 was $44,169,000, which included restricted securities of $4,989,000. The Company had 26,015,824 shares outstanding on September 30, 2000.
Primarily as a result of merger-related expenses, Curis reported a net loss of $322,869,000 or $15.19 per share, for the three-month period ended September 30, 2000, compared with a net loss of $2,995,000, or $0.28 per share, for the three-month period ended September 30, 1999. Per share amounts are on both a basic and diluted basis.
Total revenues for the three-month period ended September 30, 2000 were $66,000 as compared to $824,000 for the same period in 1999. The decrease in revenues was primarily the result of the termination of a research agreement with Biogen, Inc. in 1999, which was partially offset by revenues earned under a National Institute of Standards and Technology (NIST) grant received in November 1999.
Total operating expenses for the three-month period ended September 30, 2000 were $323,336,000, as compared to $4,138,000 for the same period in 1999..
"The fiscal quarter ended September 30, 2000 was the first for Curis following shareholder approval of the merger of Creative BioMolecules, Ontogeny, and Reprogenesis," said Doros Platika, M.D., president and chief executive officer of Curis. "It has been a busy and exciting start to a new company that is building a leadership presence in regenerative medicine.
"The quarter was marked by several research findings based upon the core developmental biology and functional genomics technologies driving the discovery of innovative therapies at Curis," said Dr. Platika. "These included a demonstration that treatment with the Sonic Hedgehog protein restored nerve function to normal in pre-clinical models of diabetic neuropathy. Additional findings showed that the Hedgehog pathway is activated following injury to peripheral nerves in pre-clinical models and plays a key role in the nerve recovery process. These studies represent critical components in our program leading up to the introduction of a Hedgehog-based therapy into clinical testing.
"Earlier in the quarter, research published in Nature (Vol. 406, 31 August 2000) demonstrated that Curis` approach to treating basal cell carcinoma is based on fundamental genetic differences between cancer cells and normal cells," said Dr. Platika. "Our compound, CUR-61414, inhibits the biological process that leads to the uncontrolled growth seen in basal cell and certain other cancers. We expect to file an Investigational New Drug (IND) application to begin human clinical testing with this compound next year.
"On the clinical front, enrollment in our Phase III clinical trial with Chondrogel was completed in September," said Dr. Platika. "Data from this trial in children with vesicoureteral reflux is expected in late 2001. Pending evaluation of this data, we expect to submit a Biologics License Application (BLA) to the U.S. FDA in the first half of 2002, and we plan to market this product ourselves.
"In October, Curis received a second $2,000,000 grant from the National Institute of Standards and Technology (NIST) to support the development of a new class of biomaterials designed to enable minimally invasive surgical procedures," said Dr. Platika. "Such procedures would significantly reduce postoperative pain and decrease the length of hospital stays, recovery time and healthcare costs. Initial applications targeted by NIST under this grant include gastroesophogeal reflux disease and stress urinary incontinence."
Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. Curis is combining insights gained through the study of developmental biology with high-throughput screening capabilities, proteins, cells and biocompatible materials to facilitate the development of new regenerative medicine therapies. For more information, please visit the Curis web site at http://www.curis.com.
The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, regulatory approval and commercialization, the impact of competitive products, patents, patent litigation, product liability, third party reimbursement, and other risks and uncertainties associated with the biotechnology industry. For additional factors that could cause actual results to differ materially, please refer to the risk factors section of the Curis joint proxy statement/prospectus filed with the Securities and Exchange Commission on June 19, 2000.
CURIS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
Three months ended Nine months ended
September 30, September 30,
2000 1999 2000 1999
Revenues $ 65,955 $ 823,573 $ 743,813 $ 2,405,760
Operating expenses:
Research and
development 6,056,255 2,708,005 10,072,461 8,072,342
General and
administrative 4,040,568 1,317,051 6,604,422 4,078,187
Stock-based
compensation 9,356,112 -- 12,495,590 64,000
Amortization
of intangible
assets 8,529,302 112,725 8,647,473 325,705
Loss on
disposition
of fixed assets 553,912 -- 248,516 --
In-process
research &
development 294,800,000 -- 294,800,000 --
Total
operating
expenses 323,336,149 4,137,781 332,868,462 12,540,234
Net loss from
operations (323,270,194) (3,314,208) (332,124,649) (10,134,474)
Interest and
other income 580,706 366,177 1,164,252 1,617,577
Interest expense (179,747) (46,528) (265,362) (114,780)
Total other
income 400,959 319,649 898,890 1,502,797
Net loss $(322,869,235)$ (2,994,559)$(331,225,759)$ (8,631,677)
Accretion and
repurchase
costs on Series
1998/A
Preferred Stock -- -- -- (2,395,559)
Net loss
applicable
to common
stockholders $(322,869,235)$ (2,994,559)$(331,225,759)$ (11,027,236)
Basic and
diluted net
loss per
common share $ (15.19)$ (0.28)$ (22.59)$ (1.04)
Weighted
average common
shares for
basic and
diluted
net loss
computation 21,250,137 10,798,008 14,662,960 10,618,696
CURIS, INC.
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
September 30, December 31,
2000 1999
ASSETS
Cash, cash equivalents and
marketable securities $ 44,168,748 $ 21,370,585
Property and equipment, net 7,437,337 2,130,158
Intangible assets 113,737,522 5,075,914
Other assets 1,386,988 315,634
Total assets $166,730,595 $ 28,892,291
LIABILITIES AND STOCKHOLDERS`
EQUITY
Accounts payable and
accrued expenses $ 8,061,659 $ 4,113,994
Debt and capital
lease obligations 5,537,264 1,356,711
Total liabilities 13,598,923 5,470,705
Total stockholders` equity 153,131,672 23,421,586
Total liabilities and
stockholders` equity $166,730,595 $ 28,892,291
CONTACT: Curis, Inc.
William B. Boni
(617) 876-0086, ext. 6506
or
Cynthia Clayton
(617) 876-0086, ext. 6641
Könnte mir jemand bitte was genaueres über die Zahlen sagen ,bin neu
an der Aktienfront.
Danke schon mal...
an der Aktienfront.
Danke schon mal...
Wie war das nochmal mit der Unterbewertung ?
Trading Spotlight
richtig gelesen.
Unterbewertet!!!
und 2002 sag ich dir , warum.
heutiger Kurs: 4$
Bis denne......
1000 Stk = 4000$
Unterbewertet!!!
und 2002 sag ich dir , warum.
heutiger Kurs: 4$
Bis denne......
1000 Stk = 4000$
Als alter Curis -Fan, bin ich auch der Meinung, dass man auf diesem Niveau einsteigen sollte. Sehr spekulativ- aber mittelfristig sehr aussichtsreich !!!
Schaut mal die Produktpipline an- im regenerativen Bereich ein Top-Invest.
Gruß L.
Schaut mal die Produktpipline an- im regenerativen Bereich ein Top-Invest.
Gruß L.
und kurz vor der Zulassung für Europa noch ein paar lustige neuigkeiten von der
Institutionellen Seite.
(alles am 31.03.01)
Am Express - 750 000 shares
Pilgrim - 516 200
Mund - 367 600
Cal -+206 600
Peq - 120 000
First -+ 77 158
Orign - 100 000
Pr. - 74 504 Stk
!!!!!!!!!!!!!!!!!!!!!!!!quelle:nas
allen Curis Aktionären noch ein paar schöne Tage.
(vor dem großen Sturm)
Institutionellen Seite.
(alles am 31.03.01)
Am Express - 750 000 shares
Pilgrim - 516 200
Mund - 367 600
Cal -+206 600
Peq - 120 000
First -+ 77 158
Orign - 100 000
Pr. - 74 504 Stk
!!!!!!!!!!!!!!!!!!!!!!!!quelle:nas
allen Curis Aktionären noch ein paar schöne Tage.
(vor dem großen Sturm)
Lieber Grast,
kannst Du mal erklären,was das bedeutet??
kannst Du mal erklären,was das bedeutet??
das sind die neupositionierungen der vorgenannten Fonds
und wieviele stücke sie neu erworben haben.
komisch , nicht? dass die sich jetzt auf einmal eindecken...?
und wieviele stücke sie neu erworben haben.
komisch , nicht? dass die sich jetzt auf einmal eindecken...?
und einen tag später die europa zulassung.
erstes produkt v. curis am markt.
jaaaaaaa$$$$$$$$$$$$$$$$$$$$$$$$$
erstes produkt v. curis am markt.
jaaaaaaa$$$$$$$$$$$$$$$$$$$$$$$$$
Curis lebt!!!!
Zulassung in Europa !!!, Mass.--(BUSINESS WIRE)--May 17, 2001--Curis, Inc. (NASDAQ:CRIS) today commented on an announcement from Stryker Corporation (NYSE: SYK) that the European Commission has granted marketing authorization for OP-1 Implant (Osteogenic Protein 1) in the 15 member countries of the European Union. The indication approved for marketing authorization is for the treatment of nonunion of the tibia of at least nine months duration, secondary to trauma, in skeletally mature patients, in cases where previous autograft has failed or use of autograft is unfeasible.
"We are delighted that Stryker has been granted marketing approval of the OP-1 Implant in the European Union. The approvals in Europe and Australia represent the first steps in generating a sustained product revenue stream for Curis," stated Doros Platika, M.D., president and chief executive officer of Curis. "OP-1 also represents one of the first regenerative medical products on the market and validates the fact that these potential products and regenerative medicines are not a future dream, but a present reality. These are products that activate the body`s ability to repair and regenerate new tissue to restore lost function. The Curis technology platform has generated a full pipeline of prospective products based on Curis` expertise in the field of developmental biology, allowing us the potential to generate a new-class of products that activate key developmental pathways to restore normal function or inhibit aberrantly activated pathways associated with malignancies."
OP-1, under license by Curis to Stryker for orthopaedic and periodontal indications in exchange for royalty payments as a percentage of sales, is the first biotechnology product recommended for use specifically in the field of orthopaedic medicine. Stryker stated in its press release that it anticipates commercial launch of OP-1 in the European Union to begin in the third quarter of 2001.
Zulassung in Europa !!!, Mass.--(BUSINESS WIRE)--May 17, 2001--Curis, Inc. (NASDAQ:CRIS) today commented on an announcement from Stryker Corporation (NYSE: SYK) that the European Commission has granted marketing authorization for OP-1 Implant (Osteogenic Protein 1) in the 15 member countries of the European Union. The indication approved for marketing authorization is for the treatment of nonunion of the tibia of at least nine months duration, secondary to trauma, in skeletally mature patients, in cases where previous autograft has failed or use of autograft is unfeasible.
"We are delighted that Stryker has been granted marketing approval of the OP-1 Implant in the European Union. The approvals in Europe and Australia represent the first steps in generating a sustained product revenue stream for Curis," stated Doros Platika, M.D., president and chief executive officer of Curis. "OP-1 also represents one of the first regenerative medical products on the market and validates the fact that these potential products and regenerative medicines are not a future dream, but a present reality. These are products that activate the body`s ability to repair and regenerate new tissue to restore lost function. The Curis technology platform has generated a full pipeline of prospective products based on Curis` expertise in the field of developmental biology, allowing us the potential to generate a new-class of products that activate key developmental pathways to restore normal function or inhibit aberrantly activated pathways associated with malignancies."
OP-1, under license by Curis to Stryker for orthopaedic and periodontal indications in exchange for royalty payments as a percentage of sales, is the first biotechnology product recommended for use specifically in the field of orthopaedic medicine. Stryker stated in its press release that it anticipates commercial launch of OP-1 in the European Union to begin in the third quarter of 2001.
Ein Aufflackern war vor ein paar Wochen auch die Genehmigung von Australien, jetzt Europa.
Hat irgendjemand eine Ahnung, wie das Verfahren bzw. die Nachreichung der Dokumente bei der FDA ablaeuft oder der Status ist?
Bei den Quartalszahlen hat man sich da ja eher pessimistisch dazu geaeussert, dass OP-1 in US ueberhaupt eine Chance hat, genehmigt zu werden:
Auszug aus Ad-Hoc vom 9. Mai: ".....Stryker indicated, however, that they are unable to predict when OP-1 for non-union fractures would be cleared for marketing approval in the United States, if at all...."
Denn falls OP-1 in USA genehmigt werden sollte, haben wir absolut realistische Chancen auf Kurse zwischen 20 und 30 USD. Damals, bei Nichtgenehmigung rutschte Curis naemlich von ca. 13 auf ca. 6 USD ab, mit Einberechnung der optimistischeren Maerkte und den Zulassungen in Europa und Australien, waeren wir jetzt sicherlich bei ca. 25 USD.
Hat irgendjemand eine Ahnung, wie das Verfahren bzw. die Nachreichung der Dokumente bei der FDA ablaeuft oder der Status ist?
Bei den Quartalszahlen hat man sich da ja eher pessimistisch dazu geaeussert, dass OP-1 in US ueberhaupt eine Chance hat, genehmigt zu werden:
Auszug aus Ad-Hoc vom 9. Mai: ".....Stryker indicated, however, that they are unable to predict when OP-1 for non-union fractures would be cleared for marketing approval in the United States, if at all...."
Denn falls OP-1 in USA genehmigt werden sollte, haben wir absolut realistische Chancen auf Kurse zwischen 20 und 30 USD. Damals, bei Nichtgenehmigung rutschte Curis naemlich von ca. 13 auf ca. 6 USD ab, mit Einberechnung der optimistischeren Maerkte und den Zulassungen in Europa und Australien, waeren wir jetzt sicherlich bei ca. 25 USD.
so,das waren die 5$
die herrschaften scheinen aufgegeben zu haben den kurs um die 5 zu
halten.
in frankfurt lief es sehr oft nach dem gleichen muster.
500 stk kauforders zu 5,9
dann 25 stk verkaufsorders zu 5,5 - 55,6
in usa im größeren stil ähnlich.
gestern abend zu börsenschluß der anstieg auf 5,49
ein gutes zeichen?
jetzt kommt cash aus den ersten produktverkäufen in die kassen.
und in ruhe kann curis die fortgeschrittenen medikamente platzieren und
die in den anfängen steckenden , entwickeln ohne in finanz. schwierigkeiten zu kommen.
entwickelt sich jetzt wirklich eine führende firma in der regenerativen medizin?
allen ehemaligen cretive biom aktionären und bis heute curis die treue gehalten habendenden
wäre es zu wünschen.ich habe jedenfalls mittwoch noch zu 5,5
ein bisselchen aufgestockt.das die eu zulassung so schnell kam,konnte ich nicht ahnen.
op-1 scheint also zu funktionieren.
viel glück , uns allen.
die herrschaften scheinen aufgegeben zu haben den kurs um die 5 zu
halten.
in frankfurt lief es sehr oft nach dem gleichen muster.
500 stk kauforders zu 5,9
dann 25 stk verkaufsorders zu 5,5 - 55,6
in usa im größeren stil ähnlich.
gestern abend zu börsenschluß der anstieg auf 5,49
ein gutes zeichen?
jetzt kommt cash aus den ersten produktverkäufen in die kassen.
und in ruhe kann curis die fortgeschrittenen medikamente platzieren und
die in den anfängen steckenden , entwickeln ohne in finanz. schwierigkeiten zu kommen.
entwickelt sich jetzt wirklich eine führende firma in der regenerativen medizin?
allen ehemaligen cretive biom aktionären und bis heute curis die treue gehalten habendenden
wäre es zu wünschen.ich habe jedenfalls mittwoch noch zu 5,5
ein bisselchen aufgestockt.das die eu zulassung so schnell kam,konnte ich nicht ahnen.
op-1 scheint also zu funktionieren.
viel glück , uns allen.
Ja,das wird was mit Curis.
Nach langer Talfahrt und Umwandlungsdisaster von ehem.Creative Bio.
in Curis glaube ich solangsam an eine Storie,bei der ich von Anfang an dabei war.
Nachkäufe haben nun meinen Schnitt etwas erträglicher werden lassen.
Bei Viropharma sah es 12 Monate genauso beschi..aus,heute bin ich wieder im plus .
viel Glück allen Curis Aktionären
Lima
Nach langer Talfahrt und Umwandlungsdisaster von ehem.Creative Bio.
in Curis glaube ich solangsam an eine Storie,bei der ich von Anfang an dabei war.
Nachkäufe haben nun meinen Schnitt etwas erträglicher werden lassen.
Bei Viropharma sah es 12 Monate genauso beschi..aus,heute bin ich wieder im plus .
viel Glück allen Curis Aktionären
Lima
keine verkaufsaufträge unter US$ 12 !
komisch,bid 5
ask 12.
island auch!
herzlichst
ipic war ja gestern der hammer..
endlich
komisch,bid 5
ask 12.
island auch!
herzlichst
ipic war ja gestern der hammer..
endlich
uuoops,wer erwacht denn da zum leben?
Nachdem es täglich mehrere Umsätze in dieser Aktie in Deutschland gibt, müssen ja wohl ein paar Leutchen investiert sein. Seid IHr das?
was hier noch fehlt ist ein chart
außerdem ist es bald 12monate her daß die fusion wirklichkeit wurde ich vermute mal daß es da lock-up termine geben wird mit 1 august,...
da der kurs bereits auf den selben (grob geschätzt) tiefststand gefallen ist den die creative biomolecules aktie hatte (trotz 10:3 umtauschverhältniß also nochmal auf ein drittel des alten cbmi Lows)
rechne ich nicht mit einer verkaufswelle sondern mit höheren Kursen. schließlich hat sich der unternehmenswert durch die fusion sicher nicht reduziert.
dann gabs ja auch noch die erste produktzulassung in europa.
ISt also nur eine frage der zeit bis wir wieder zumindest auf 27$ sind,...
da es eine wartegeschichte ist sollte man aber nur einen teil seines kapitals investieren und sich nicht die Kursanstiege der anderen biotechs wie VRTX ,CALP,CBST,ENZ(nicht enzn!),VXGN,CRXA,AVGN,SCIO,TTP,CRGN,PCOP,EXEL,CELG,....
entgehen lassen
außerdem ist es bald 12monate her daß die fusion wirklichkeit wurde ich vermute mal daß es da lock-up termine geben wird mit 1 august,...
da der kurs bereits auf den selben (grob geschätzt) tiefststand gefallen ist den die creative biomolecules aktie hatte (trotz 10:3 umtauschverhältniß also nochmal auf ein drittel des alten cbmi Lows)
rechne ich nicht mit einer verkaufswelle sondern mit höheren Kursen. schließlich hat sich der unternehmenswert durch die fusion sicher nicht reduziert.
dann gabs ja auch noch die erste produktzulassung in europa.
ISt also nur eine frage der zeit bis wir wieder zumindest auf 27$ sind,...
da es eine wartegeschichte ist sollte man aber nur einen teil seines kapitals investieren und sich nicht die Kursanstiege der anderen biotechs wie VRTX ,CALP,CBST,ENZ(nicht enzn!),VXGN,CRXA,AVGN,SCIO,TTP,CRGN,PCOP,EXEL,CELG,....
entgehen lassen
1 stunde vor dem dienstag börsenschluss gabs übrigens news
Tuesday July 3, 12:01 pm Eastern Time
Press Release
Curis and Micromet Sign Strategic Alliance Incorporating Innovative
Antibody Therapeutic Development and Genomics Technology
CAMBRIDGE, Mass. USA & MUNICH, Germany--(BW HealthWire)--July 3, 2001--Curis, Inc. (NASDAQ: CRIS - news)
and Micromet AG, Martinsried, Germany have entered into an extensive agreement covering research, product development, and
technology exchange. Curis transfers its intellectual property portfolio and licenses in the field of single chain antibody technology
to Micromet. During the current year Curis will receive US$14 million in an up-front payment in cash, and a planned equity
participation in Micromet. There will be additional royalties and profit sharing payments to both Curis and Micromet from the
development of therapeutic products.
Furthermore, Curis receives exclusive rights to Micromet`s single cell genomics technology (SCAGE) for the field of stem cell and
genomic research. Data from this joint discovery program will be integrated into a database whereby both companies will mine
targets suitable for antibody drug development. The Companies will co-develop selected therapeutic antibodies, while all rights to
small molecule targets will rest with Curis, and revenue from third party usage will be shared by both companies. There will be
additional royalties and profit sharing to both Curis and Micromet from stem cell genomics and database research.
``Curis` collaboration and strategic alliance with Micromet, AG combines our complementary expertise, technology, product
platforms in developmental biology and small molecule discovery capacities unlocking tremendous potential,`` said Dan Passeri,
Senior Vice President, Corporate Development and Strategic Planning. ``It represents an important strategic development for
Curis to become a leader in regenerative medicine. Micromet consolidates its position as a dominant force in the area of single
chain antibody drugs,`` added Mr. Passeri.
``This extensive strategic alliance captures the synergies generated by Micromet`s expertise in discovering and developing
innovative antibody therapeutics as drug candidates with Curis` strength in mining the genome to generate validated targets,`` said
Doros Platika, M.D., President and Chief Executive Officer of Curis. ``In many instances, antibody agonists and antagonists
would be much easier to produce and work with in developing a drug candidate than the actual protein ligand regulating these
pathways. We believe Micromet`s SCAGE technology will be one of the critical keys to unlocking the power of stem cell
genomics and drug discovery.``
Christian Itin, Vice-President, Corporate Development at Micromet AG, reiterated that ``combining SCAGE with Curis` stem cell
expertise will develop a unique platform to analyze the earliest stages of stem cell differentiation. Furthermore, Micromet`s
expertise in the design and development of innovative drug formats will start releasing the value inherent in the intellectual property
in the area of single-chain antibody technology. Based on this technology, Micromet has already established the BiTE(TM)
(``Bispecific T-cell engagers``) drug format for elimination of pathogenic cells in cancer, autoimmune and inflammatory disease.
Further drug formats will be developed for modulating the activity of normal and aberrant cell function.``
Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. The Company is
combining insights gained through the study of developmental biology with high-throughput screening capabilities, proteins, cells
and biocompatible materials to facilitate the development of new regenerative medicine therapies. For more information, please
visit the Curis web site at www.curis.com.
Micromet AG, a privately held, Munich-based biotechnology company, designs and develops novel antibody-based drugs for treatment of cancer, autoimmune and
inflammatory disease. The Company has established the BiTE(TM) technology (``Bispecific T cell engagers``), a unique drug format that leverages the outstanding
cytotoxic potential of T cells, the most powerful `killer cells` of the human immune system. Micromet`s pipeline of drug candidates includes BiTE(TM) molecules as
well as fully human antibodies, with two products now approaching clinical Phase I trials. The Company has integrated drug development capabilities. Micromet has
investments from leading international life science investors. For more information go to www.micromet.de
The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties including, without limitation, risks
associated with the inherent uncertainty of pharmaceutical research, product development, regulatory approval and commercialization, status of human clinical trials,
the impact of competitive products, patents, patent litigation, product liability, third party reimbursement, corporate collaborations, and other risks and uncertainties
associated with the biotechnology industry. For additional factors that could cause actual results to differ materially, please refer to the risk factors section of the
Curis Annual Report on Form 10-K for the year ended December 31, 2000 filed with the Securities and Exchange Commission on March 30, 2001.
Contact:
Curis, Inc.:
Henry W. McCusker
+01-617-503-6641
or
Dan Passeri
+01-617-503-6680
or
Micromet AG:
Evelyn Wolf
+49-89-895-27751
or
Christian Itin
+49-89-895-27770
or
Noonan/Russo:
Renee Connolly
+01-212-696-4455
x227
or
Sharon Weinstein
+01-212-696-4455
x334
Tuesday July 3, 12:01 pm Eastern Time
Press Release
Curis and Micromet Sign Strategic Alliance Incorporating Innovative
Antibody Therapeutic Development and Genomics Technology
CAMBRIDGE, Mass. USA & MUNICH, Germany--(BW HealthWire)--July 3, 2001--Curis, Inc. (NASDAQ: CRIS - news)
and Micromet AG, Martinsried, Germany have entered into an extensive agreement covering research, product development, and
technology exchange. Curis transfers its intellectual property portfolio and licenses in the field of single chain antibody technology
to Micromet. During the current year Curis will receive US$14 million in an up-front payment in cash, and a planned equity
participation in Micromet. There will be additional royalties and profit sharing payments to both Curis and Micromet from the
development of therapeutic products.
Furthermore, Curis receives exclusive rights to Micromet`s single cell genomics technology (SCAGE) for the field of stem cell and
genomic research. Data from this joint discovery program will be integrated into a database whereby both companies will mine
targets suitable for antibody drug development. The Companies will co-develop selected therapeutic antibodies, while all rights to
small molecule targets will rest with Curis, and revenue from third party usage will be shared by both companies. There will be
additional royalties and profit sharing to both Curis and Micromet from stem cell genomics and database research.
``Curis` collaboration and strategic alliance with Micromet, AG combines our complementary expertise, technology, product
platforms in developmental biology and small molecule discovery capacities unlocking tremendous potential,`` said Dan Passeri,
Senior Vice President, Corporate Development and Strategic Planning. ``It represents an important strategic development for
Curis to become a leader in regenerative medicine. Micromet consolidates its position as a dominant force in the area of single
chain antibody drugs,`` added Mr. Passeri.
``This extensive strategic alliance captures the synergies generated by Micromet`s expertise in discovering and developing
innovative antibody therapeutics as drug candidates with Curis` strength in mining the genome to generate validated targets,`` said
Doros Platika, M.D., President and Chief Executive Officer of Curis. ``In many instances, antibody agonists and antagonists
would be much easier to produce and work with in developing a drug candidate than the actual protein ligand regulating these
pathways. We believe Micromet`s SCAGE technology will be one of the critical keys to unlocking the power of stem cell
genomics and drug discovery.``
Christian Itin, Vice-President, Corporate Development at Micromet AG, reiterated that ``combining SCAGE with Curis` stem cell
expertise will develop a unique platform to analyze the earliest stages of stem cell differentiation. Furthermore, Micromet`s
expertise in the design and development of innovative drug formats will start releasing the value inherent in the intellectual property
in the area of single-chain antibody technology. Based on this technology, Micromet has already established the BiTE(TM)
(``Bispecific T-cell engagers``) drug format for elimination of pathogenic cells in cancer, autoimmune and inflammatory disease.
Further drug formats will be developed for modulating the activity of normal and aberrant cell function.``
Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. The Company is
combining insights gained through the study of developmental biology with high-throughput screening capabilities, proteins, cells
and biocompatible materials to facilitate the development of new regenerative medicine therapies. For more information, please
visit the Curis web site at www.curis.com.
Micromet AG, a privately held, Munich-based biotechnology company, designs and develops novel antibody-based drugs for treatment of cancer, autoimmune and
inflammatory disease. The Company has established the BiTE(TM) technology (``Bispecific T cell engagers``), a unique drug format that leverages the outstanding
cytotoxic potential of T cells, the most powerful `killer cells` of the human immune system. Micromet`s pipeline of drug candidates includes BiTE(TM) molecules as
well as fully human antibodies, with two products now approaching clinical Phase I trials. The Company has integrated drug development capabilities. Micromet has
investments from leading international life science investors. For more information go to www.micromet.de
The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties including, without limitation, risks
associated with the inherent uncertainty of pharmaceutical research, product development, regulatory approval and commercialization, status of human clinical trials,
the impact of competitive products, patents, patent litigation, product liability, third party reimbursement, corporate collaborations, and other risks and uncertainties
associated with the biotechnology industry. For additional factors that could cause actual results to differ materially, please refer to the risk factors section of the
Curis Annual Report on Form 10-K for the year ended December 31, 2000 filed with the Securities and Exchange Commission on March 30, 2001.
Contact:
Curis, Inc.:
Henry W. McCusker
+01-617-503-6641
or
Dan Passeri
+01-617-503-6680
or
Micromet AG:
Evelyn Wolf
+49-89-895-27751
or
Christian Itin
+49-89-895-27770
or
Noonan/Russo:
Renee Connolly
+01-212-696-4455
x227
or
Sharon Weinstein
+01-212-696-4455
x334
gemeinschaftsfirma mit elan wird gegründet
CURIS INC (CRIS)
form 8-K
ITEM 5. OTHER EVENTS.
On June 29, 2001, Curis, Inc. (the "Company") entered into a binding letter of intent with Elan International Services, Ltd. ("EIS"), Elan Pharma International
Limited, an affiliate of EIS ("EPIL"), and Neuralab Limited, a wholly-owned indirect subsidiary of Elan Corporation, plc ("Neuralab"), pursuant to which the
Company and EIS will form and fund a new corporation ("NewCo") to develop compounds that are hedgehog agonists for the treatment and/or prevention of human
neurological disorders.
The letter of intent provides that upon the consummation of a definitive agreement the Company will (i) issue to EIS shares of a newly-created class of convertible
exchangeable preferred stock valued at $12,015,000 and which are convertible into shares of the Company`s common stock at a price per share of $14.12; (ii)
issue to EPIL a convertible promissory note in the aggregate principal amount of up to $8,010,000 (excluding capitalized interest) in order to fund the Company`s
development funding contributions to NewCo, which note shall be convertible into shares of the Company`s common stock at a price per share of $8.63 in
connection with the credit facility; (iii) issue to EIS 546,448 shares of the Company`s common stock at a price per share of $7.32; and (iv) issue to EIS a five-year
warrant to purchase 50,000 shares of the Company`s common stock at a price per share of $10.46.
The letter of intent sets forth the terms and conditions for funding and licensing technology to NewCo. The letter of intent provides that upon the consummation of
definitive documents the Company will subscribe for a controlling interest in a joint venture with EIS. EIS, however, will have certain rights to prevent NewCo from
undertaking certain fundamental transactions without its consent.
The letter of intent provides that upon consummation of definitive documents the Company will grant an exclusive license to, and Neuralab will grant a non-exclusive
license to, NewCo with respect to certain technology related to NewCo`s business purpose. In addition, Neuralab will hold a first option to commercialize and a first
right to manufacture any compounds developed by NewCo.
CURIS INC (CRIS)
form 8-K
ITEM 5. OTHER EVENTS.
On June 29, 2001, Curis, Inc. (the "Company") entered into a binding letter of intent with Elan International Services, Ltd. ("EIS"), Elan Pharma International
Limited, an affiliate of EIS ("EPIL"), and Neuralab Limited, a wholly-owned indirect subsidiary of Elan Corporation, plc ("Neuralab"), pursuant to which the
Company and EIS will form and fund a new corporation ("NewCo") to develop compounds that are hedgehog agonists for the treatment and/or prevention of human
neurological disorders.
The letter of intent provides that upon the consummation of a definitive agreement the Company will (i) issue to EIS shares of a newly-created class of convertible
exchangeable preferred stock valued at $12,015,000 and which are convertible into shares of the Company`s common stock at a price per share of $14.12; (ii)
issue to EPIL a convertible promissory note in the aggregate principal amount of up to $8,010,000 (excluding capitalized interest) in order to fund the Company`s
development funding contributions to NewCo, which note shall be convertible into shares of the Company`s common stock at a price per share of $8.63 in
connection with the credit facility; (iii) issue to EIS 546,448 shares of the Company`s common stock at a price per share of $7.32; and (iv) issue to EIS a five-year
warrant to purchase 50,000 shares of the Company`s common stock at a price per share of $10.46.
The letter of intent sets forth the terms and conditions for funding and licensing technology to NewCo. The letter of intent provides that upon the consummation of
definitive documents the Company will subscribe for a controlling interest in a joint venture with EIS. EIS, however, will have certain rights to prevent NewCo from
undertaking certain fundamental transactions without its consent.
The letter of intent provides that upon consummation of definitive documents the Company will grant an exclusive license to, and Neuralab will grant a non-exclusive
license to, NewCo with respect to certain technology related to NewCo`s business purpose. In addition, Neuralab will hold a first option to commercialize and a first
right to manufacture any compounds developed by NewCo.
+8% heute und dass bei dem markt -auch nette umsätze
vielleicht ist jetzt die wende da
vielleicht ist jetzt die wende da
schnuckeliger ausbruch mit +17% das liegt bestimmt an den mit elan abgschlossenen
letter of intend da ist ja von wesentlich höheren aktienkursen die rede.
letter of intend da ist ja von wesentlich höheren aktienkursen die rede.
schad daß sich außer mir niemand für curis interessiert
dabei ist sie wirklich spotbillig und gerade am ausbruch nach oben
die relative stärke im vergleich zu den restlichen biotechs in den letzten tagen ist nicht zu übersehen.
news von heute:
Curis Added to the Russell 2000 and 3000 Indexes
WEDNESDAY, JULY 11, 2001 7:00 AM
- BusinessWire
CAMBRIDGE, Mass., Jul 11, 2001 (BW HealthWire) -- Curis, Inc. (NASDAQ:CRIS) today announced that it had been
added to the list of companies making up the Russell 2000 and 3000 Indexes.
"We are extremely pleased to be a member of the Russell 2000 and 3000 Indexes," said Doros Platika, M.D.,
President and Chief Executive Officer of Curis. "Our inclusion represents another significant milestone, and more
importantly, an acknowledgement of the technological value we have been able to create at Curis. Joining theselect
group of companies included in the Russell Indexes reflects the growing recognition of regenerative medicine and its
potential clinical and commercial value."
The Russell 2000 and 3000 Indexes compiles and maintains 21 U.S. Equity indexes developed by the Frank Russell
Company (http://www.russell.com) and represents approximately 98 percent of the investable U.S. equity market.
Russell adjusts its indexes annually in order to accurately rank the 3000 largest companies in the U.S. stock market
by market capitalization. The Russell indexes are widely used as performance benchmarks for measuring fund and
investment performance.
Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. The Company
is combining insights gained through the study of developmental biology with high-throughput screening capabilities,
proteins, cells and biocompatible materials to facilitate the development of new regenerative medicine therapies. For
more information, please visit the Curis web site at www.curis.com
dabei ist sie wirklich spotbillig und gerade am ausbruch nach oben
die relative stärke im vergleich zu den restlichen biotechs in den letzten tagen ist nicht zu übersehen.
news von heute:
Curis Added to the Russell 2000 and 3000 Indexes
WEDNESDAY, JULY 11, 2001 7:00 AM
- BusinessWire
CAMBRIDGE, Mass., Jul 11, 2001 (BW HealthWire) -- Curis, Inc. (NASDAQ:CRIS) today announced that it had been
added to the list of companies making up the Russell 2000 and 3000 Indexes.
"We are extremely pleased to be a member of the Russell 2000 and 3000 Indexes," said Doros Platika, M.D.,
President and Chief Executive Officer of Curis. "Our inclusion represents another significant milestone, and more
importantly, an acknowledgement of the technological value we have been able to create at Curis. Joining theselect
group of companies included in the Russell Indexes reflects the growing recognition of regenerative medicine and its
potential clinical and commercial value."
The Russell 2000 and 3000 Indexes compiles and maintains 21 U.S. Equity indexes developed by the Frank Russell
Company (http://www.russell.com) and represents approximately 98 percent of the investable U.S. equity market.
Russell adjusts its indexes annually in order to accurately rank the 3000 largest companies in the U.S. stock market
by market capitalization. The Russell indexes are widely used as performance benchmarks for measuring fund and
investment performance.
Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. The Company
is combining insights gained through the study of developmental biology with high-throughput screening capabilities,
proteins, cells and biocompatible materials to facilitate the development of new regenerative medicine therapies. For
more information, please visit the Curis web site at www.curis.com
Hallo 4now,
es gibt neben Dir noch andere Interessierte und Investierte.
Doch nach dem Schock der Umstrukturierung von Creative
in Curis ist mein Depot dermaßen abgestürzt, dass ich
nun auf meine langfristige Anlagestrategie hoffe.
Ich bin aber nicht sehr zuversichtlich, meine Einstiegskurse
von umgerechnet 38 € wiederzusehen. Aber offensichtlich
tut sich nun etwas in der richtigen Richtung, und
ich bin etwas optimistischer im Hinblick auf steigende Kurse.
Und wie siehst Du das?
es gibt neben Dir noch andere Interessierte und Investierte.
Doch nach dem Schock der Umstrukturierung von Creative
in Curis ist mein Depot dermaßen abgestürzt, dass ich
nun auf meine langfristige Anlagestrategie hoffe.
Ich bin aber nicht sehr zuversichtlich, meine Einstiegskurse
von umgerechnet 38 € wiederzusehen. Aber offensichtlich
tut sich nun etwas in der richtigen Richtung, und
ich bin etwas optimistischer im Hinblick auf steigende Kurse.
Und wie siehst Du das?
Nach Regen kommt Sonne!
Jetzt noch Curis einkaufen!
Ich wette auf Kurse um die 20€ wenn der Markt mal dreht.
Lima
Jetzt noch Curis einkaufen!
Ich wette auf Kurse um die 20€ wenn der Markt mal dreht.
Lima
Curis wurde im letzten INVESTOR über alles empfohlen.Es erfolgte eine sehr umfangreiche Analyse mit einem sehr positiven Ausblick.
Curis - wird im Investor als regenerative Medizin--3 Spezialgebiete auf einen Schlag-- bezeichnet. Demnach besitzt Curis eine chancenreiche Forschungs - Pipeline.
Kursziel für Trader: 14,5US Dollar
3-5 Jahre: 35 US Dollar
Stopp: 4US Dollar
Liotosa
Kursziel für Trader: 14,5US Dollar
3-5 Jahre: 35 US Dollar
Stopp: 4US Dollar
Liotosa
Curis Added to the Russell 2000 and 3000 Indexes
CAMBRIDGE, Mass., Jul 11, 2001 (BW HealthWire) -- Curis, Inc. (NASDAQ: CRIS) today announced that it had been added to the list of companies making up the Russell 2000 and 3000 Indexes.
"We are extremely pleased to be a member of the Russell 2000 and 3000 Indexes," said Doros Platika, M.D., President and Chief Executive Officer of Curis. "Our inclusion represents another significant milestone, and more importantly, an acknowledgement of the technological value we have been able to create at Curis. Joining theselect group of companies included in the Russell Indexes reflects the growing recognition of regenerative medicine and its potential clinical and commercial value."
The Russell 2000 and 3000 Indexes compiles and maintains 21 U.S. Equity indexes developed by the Frank Russell Company (http://www.russell.com) and represents approximately 98 percent of the investable U.S. equity market. Russell adjusts its indexes annually in order to accurately rank the 3000 largest companies in the U.S. stock market by market capitalization. The Russell indexes are widely used as performance benchmarks for measuring fund and investment performance.
Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. The Company is combining insights gained through the study of developmental biology with high-throughput screening capabilities, proteins, cells and biocompatible materials to facilitate the development of new regenerative medicine therapies. For more information, please visit the Curis web site at www.curis.com
The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, regulatory approval and commercialization, the impact of competitive products, patents, patent litigation, product liability, third party reimbursement, and other risks and uncertainties associated with the biotechnology industry. For additional factors that could cause actual results to differ materially, please refer to the risk factors section of the Curis Registration Statement filed on Form S-1 with the Securities and Exchange Commission on December 19, 2000 and Quarterly Report on Form 10-Q/A filed with the Securities and Exchange Commission on December 6, 2000.
CONTACT: Curis, Inc.
Henry W. McCusker
617-503-6641
or
Noonan/Russo Communications
212-696-4455
Renee Connolly (media), x227
Sharon Weinstein (investor), x334
CAMBRIDGE, Mass., Jul 11, 2001 (BW HealthWire) -- Curis, Inc. (NASDAQ: CRIS) today announced that it had been added to the list of companies making up the Russell 2000 and 3000 Indexes.
"We are extremely pleased to be a member of the Russell 2000 and 3000 Indexes," said Doros Platika, M.D., President and Chief Executive Officer of Curis. "Our inclusion represents another significant milestone, and more importantly, an acknowledgement of the technological value we have been able to create at Curis. Joining theselect group of companies included in the Russell Indexes reflects the growing recognition of regenerative medicine and its potential clinical and commercial value."
The Russell 2000 and 3000 Indexes compiles and maintains 21 U.S. Equity indexes developed by the Frank Russell Company (http://www.russell.com) and represents approximately 98 percent of the investable U.S. equity market. Russell adjusts its indexes annually in order to accurately rank the 3000 largest companies in the U.S. stock market by market capitalization. The Russell indexes are widely used as performance benchmarks for measuring fund and investment performance.
Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. The Company is combining insights gained through the study of developmental biology with high-throughput screening capabilities, proteins, cells and biocompatible materials to facilitate the development of new regenerative medicine therapies. For more information, please visit the Curis web site at www.curis.com
The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, regulatory approval and commercialization, the impact of competitive products, patents, patent litigation, product liability, third party reimbursement, and other risks and uncertainties associated with the biotechnology industry. For additional factors that could cause actual results to differ materially, please refer to the risk factors section of the Curis Registration Statement filed on Form S-1 with the Securities and Exchange Commission on December 19, 2000 and Quarterly Report on Form 10-Q/A filed with the Securities and Exchange Commission on December 6, 2000.
CONTACT: Curis, Inc.
Henry W. McCusker
617-503-6641
or
Noonan/Russo Communications
212-696-4455
Renee Connolly (media), x227
Sharon Weinstein (investor), x334
Leider ist mein Englisch nicht so gut. Könntest du eine kurze Zusammenfassung geben?
Danke im Voraus
Liotosa
Danke im Voraus
Liotosa
über das übersetzungsprogramm ist es einfacher:
Curis hinzugefügt den Indexen Russell 2000 und 3000 Cambridge, Mass., Jul 11, 2001 (Bw HealthWire) -- Curis, Inc. (Nasdaq: CRIS) verkündete heute, daß es der Liste der Firmen hinzugefügt worden war, die herauf die Indexe Russell 2000 und 3000 bilden. " wir freuen extrem, uns ein Bauteil des Russell 2000 zu sein und 3000 Indexe, ", sagte Doros Platika, M.D., Präsident und Generaldirektor von Curis. " unsere Einbeziehung stellt einen anderen bedeutenden Meilenstein und wichtiger, eine Quittung des technologischen Wertes dar, den wir gekonnt haben, bei Curis zu erstellen. Verbindene theselectgruppe Firmen, die in den Indexen Russell umfaßt werden, reflektiert die wachsende Anerkennung der verbessernden Medizin und seines möglichen klinischen und Marktwerts. ", Die Indexe Russell 2000 und 3000 kompiliert und behält 21 US-Billigkeit Indexe bei, die durch Frank Russell Company (http://www.russell.com) entwickelt werden und stellt ungefähr 98 Prozent des investable US-Billigkeit Marktes dar. Russell justiert seine Indexe jährlich, um die 3000 größten Firmen in der US-Börse durch Marktkapitalisierung genau zu ordnen. Die Indexe Russell werden allgemein wie Leistung Benchmark für messende Kapital und Investitionleistung verwendet. Curis, Inc. entwickelt die Produkte, die auf Technologien auf dem auftauchenden Gebiet der verbessernden Medizin basieren. Die Firma kombiniert die Einblicke, die durch die Studie der Entwicklungsbiologie mit Hochdurchsatzsiebungfähigkeiten, Proteinen, Zellen und biocompatible Materialien gewonnen werden, um die Entwicklung der neuen verbessernden Medizintherapien zu erleichtern. Zu mehr Information besuchen Sie bitte die Web site Curis an www.curis.com Die Anweisungen in diesen Nachrichten geben frei, die nicht historische Tatsachen Vorwärts-forward-looking Anweisungen sind, deren Gefahren und Ungewißheiten einschließlich, ohne Beschränkung, die Gefahren miteinbeziehen Sie, die mit der zugehörigen Ungewißheit der pharmazeutischen Forschung dazugehörig sind, Produktentwicklung, Genehmigung durch die zuständige Aufsichtsbehörde und Kommerzialisierung, die Auswirkung der konkurrierenden Produkte, Patente, Patentrechtsstreit, Zuverläßlichkeit von Produkten, Vergütung des dritten Beteiligten und andere Gefahren und Ungewißheiten, die mit der Biotechnologieindustrie dazugehörig sind. Für zusätzliche Faktoren, die tatsächliche Resultate veranlassen konnten, um sich materiell zu unterscheiden, das Gefahr Faktorkapitel der Anweisung Ausrichtung Curis bitte anzusprechen archiviert auf Formular S-1 mit den Aktien und der Austauschkommission an Dezember 19, 2000 und vierteljährlicher Report auf Formular 10-Q/A archiviert mit den Aktien und der Austauschkommission an Dezember 6, 2000.
Curis hinzugefügt den Indexen Russell 2000 und 3000 Cambridge, Mass., Jul 11, 2001 (Bw HealthWire) -- Curis, Inc. (Nasdaq: CRIS) verkündete heute, daß es der Liste der Firmen hinzugefügt worden war, die herauf die Indexe Russell 2000 und 3000 bilden. " wir freuen extrem, uns ein Bauteil des Russell 2000 zu sein und 3000 Indexe, ", sagte Doros Platika, M.D., Präsident und Generaldirektor von Curis. " unsere Einbeziehung stellt einen anderen bedeutenden Meilenstein und wichtiger, eine Quittung des technologischen Wertes dar, den wir gekonnt haben, bei Curis zu erstellen. Verbindene theselectgruppe Firmen, die in den Indexen Russell umfaßt werden, reflektiert die wachsende Anerkennung der verbessernden Medizin und seines möglichen klinischen und Marktwerts. ", Die Indexe Russell 2000 und 3000 kompiliert und behält 21 US-Billigkeit Indexe bei, die durch Frank Russell Company (http://www.russell.com) entwickelt werden und stellt ungefähr 98 Prozent des investable US-Billigkeit Marktes dar. Russell justiert seine Indexe jährlich, um die 3000 größten Firmen in der US-Börse durch Marktkapitalisierung genau zu ordnen. Die Indexe Russell werden allgemein wie Leistung Benchmark für messende Kapital und Investitionleistung verwendet. Curis, Inc. entwickelt die Produkte, die auf Technologien auf dem auftauchenden Gebiet der verbessernden Medizin basieren. Die Firma kombiniert die Einblicke, die durch die Studie der Entwicklungsbiologie mit Hochdurchsatzsiebungfähigkeiten, Proteinen, Zellen und biocompatible Materialien gewonnen werden, um die Entwicklung der neuen verbessernden Medizintherapien zu erleichtern. Zu mehr Information besuchen Sie bitte die Web site Curis an www.curis.com Die Anweisungen in diesen Nachrichten geben frei, die nicht historische Tatsachen Vorwärts-forward-looking Anweisungen sind, deren Gefahren und Ungewißheiten einschließlich, ohne Beschränkung, die Gefahren miteinbeziehen Sie, die mit der zugehörigen Ungewißheit der pharmazeutischen Forschung dazugehörig sind, Produktentwicklung, Genehmigung durch die zuständige Aufsichtsbehörde und Kommerzialisierung, die Auswirkung der konkurrierenden Produkte, Patente, Patentrechtsstreit, Zuverläßlichkeit von Produkten, Vergütung des dritten Beteiligten und andere Gefahren und Ungewißheiten, die mit der Biotechnologieindustrie dazugehörig sind. Für zusätzliche Faktoren, die tatsächliche Resultate veranlassen konnten, um sich materiell zu unterscheiden, das Gefahr Faktorkapitel der Anweisung Ausrichtung Curis bitte anzusprechen archiviert auf Formular S-1 mit den Aktien und der Austauschkommission an Dezember 19, 2000 und vierteljährlicher Report auf Formular 10-Q/A archiviert mit den Aktien und der Austauschkommission an Dezember 6, 2000.
Danke ! Liotosa
Curis hält sich die letzten Tage richtig gut.
Bald wird die Geduld der Aktionäre belohnt werden!!
Bald wird die Geduld der Aktionäre belohnt werden!!
forschungsfirmen mit focus auf embry. stammzellen fallen heute.
curis steigt. Warum?
könnte es mit der zusammenarbeit mit aegera auf dem gebiet der adulten stammzellen zusammenhängen?
ihr wisst doch.......die 45 mill. kapitalaufnahme im nov.
ein teil floss in diese kooperation.
viele grüße auch von mir hier an alle curisaktionäre.
curis steigt. Warum?
könnte es mit der zusammenarbeit mit aegera auf dem gebiet der adulten stammzellen zusammenhängen?
ihr wisst doch.......die 45 mill. kapitalaufnahme im nov.
ein teil floss in diese kooperation.
viele grüße auch von mir hier an alle curisaktionäre.
also ich meine die steigt ganz einfach weil sie fundamental unterbewertet ist.
wenn die alten creative biomolecules aktien zwischen 2 und 12 $ bewertet
wurden muss nach dem 10:3 der neue wert zumindest zwischen 6 und 36$ liegen.
Zusaetlich wurden aber 2 firmen hinzugefuegt und die forschung ist ebenfalls um
1 jahr fortgeschritten. weiters gabs die erste produktzulassung in europa
und die fuer usa fuerdas selbe produkt steht an.
also sollte cris ja wohl 20$-xxx$ wert sein !
wenn also weiter oben Wurlaub meint er waere fuer 38$ eingestiegen und jetzt daran zweifelt ob er jemals wieder dort hinkommt.
mein ich dass dies doch einer fairen bewertung entsprechen wuerde.
Marktzulassung des Knochenersatzproduktes in USA waer da sicher gut um die weitere
forschung zu finanzieren. der cashbestand laut finance.yahoo.com ist mit 2.12$ nicht ueberwaeltigend aber auch nicht schlecht
VRTX hat 6$/aktie.
wenn die alten creative biomolecules aktien zwischen 2 und 12 $ bewertet
wurden muss nach dem 10:3 der neue wert zumindest zwischen 6 und 36$ liegen.
Zusaetlich wurden aber 2 firmen hinzugefuegt und die forschung ist ebenfalls um
1 jahr fortgeschritten. weiters gabs die erste produktzulassung in europa
und die fuer usa fuerdas selbe produkt steht an.
also sollte cris ja wohl 20$-xxx$ wert sein !
wenn also weiter oben Wurlaub meint er waere fuer 38$ eingestiegen und jetzt daran zweifelt ob er jemals wieder dort hinkommt.
mein ich dass dies doch einer fairen bewertung entsprechen wuerde.
Marktzulassung des Knochenersatzproduktes in USA waer da sicher gut um die weitere
forschung zu finanzieren. der cashbestand laut finance.yahoo.com ist mit 2.12$ nicht ueberwaeltigend aber auch nicht schlecht
VRTX hat 6$/aktie.
sehen wir naechste woche die 10$ marke ?
mit 6.75$ haben wir ja fast am wochen hoechst geschlossen,...
mit 6.75$ haben wir ja fast am wochen hoechst geschlossen,...
Curis and Aegera Announce Breakthrough Adult Skin-Derived Stem Cell Research Reported in September Issue of Nature Cell Biology
CAMBRIDGE, Mass. & MONTREAL--(BW HealthWire)--Aug. 13, 2001--
Opens pathways to derivation of multipotent stem cells from adult skin
Curis, Inc. (NASDAQ:CRIS) and Aegera Therapeutics Inc. today announced publication in the journal Nature Cell Biology of a breakthrough technique in stem cell research using adult human skin.
Professor Freda Miller`s findings discovered at McGill University`s Montreal Neurological Institute, Aegera`s academic collaborator, indicate that adult skin is a source of multipotent stem cells which can be directed toward neuronal or mesodermal development, including neurons, glia, smooth muscle cells and adipocytes.
Quoting from Dr. Miller`s article, "These findings indicate that adult tissues contain tissue-biased stem cells,... that may be much more `plastic` than previously appreciated... the ability to readily isolate and expand such a stem cell, from an accessible potentially autologous source such as human skin, has important therapeutic implications."
Curis, Inc. and Aegera Therapeutics Inc. entered into a licensing and research agreement in January 2001, under which Aegera granted to Curis an exclusive worldwide license on Aegera`s skin-derived, adult stem cell technologies. The agreement established a broad collaboration to investigate the therapeutic potential of these technologies in neurological, pancreatic and cardiovascular disorders. Research is to be conducted at Curis, Aegera, and McGill University`s Montreal Neurological Institute.
Doros Platika, M.D., president and chief executive officer of Curis states, "We are delighted to see confirmation of our hypothesis that stem cells present in adult skin may be able to give rise to a variety of cell types that go beyond their tissue of origin. Combining Curis` expertise in stem cells, growth factors and small molecules, with Aegera`s technology, may allow the treatment of various diseases using stem cells derived from a very accessible adult source. This will also avoid any ethical concerns surrounding the use of embryonic stem cells. The focus of our collaboration is in the field of Diabetes, Neurology and Cardiovascular medicine."
Mr. Michael Atkin, Aegera`s president commented, "Dr. Freda Miller`s dramatic proof of principle for generation of multipotent stem cells from adult skin offers hope of providing a safe, non-invasive and ethically appealing source of stem cells that our society can broadly welcome. I congratulate Dr. Miller and her team on their vision and commitment, which I believe to be equalled by our partners at Curis."
About Curis, Inc.
Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. The Company is combining insights gained through the study of developmental biology with high-throughput screening capabilities, proteins, cells and biocompatible materials to facilitate the development of new regenerative medicine therapies. For more information, please visit the Curis web site and view our webcast productions on Monday, August 13, 2001, at www.curis.com.
About Aegera Therapeutics, Inc.
Aegera Therapeutics Inc. is a privately-held biotechnology company headquartered in Montreal, Canada. In addition to the Company`s stem cell focus, Aegera is developing small molecule drugs to treat central and peripheral nerve diseases, and in cancer to restore normal cell-death mechanisms by inducing apoptosis. For more information, please visit the Aegera web site at www.aegera.com.
The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, regulatory approval and commercialization, the impact of competitive products, patents, patent litigation, product liability, third party reimbursement, and other risks and uncertainties associated with the biotechnology industry. For additional factors that could cause actual results to differ materially, please refer to the risk factors section of the Curis Annual Report on Form 10-k for the year ended December 31,2000 with the Securities and Exchange Commission on March 30, 2001
CAMBRIDGE, Mass. & MONTREAL--(BW HealthWire)--Aug. 13, 2001--
Opens pathways to derivation of multipotent stem cells from adult skin
Curis, Inc. (NASDAQ:CRIS) and Aegera Therapeutics Inc. today announced publication in the journal Nature Cell Biology of a breakthrough technique in stem cell research using adult human skin.
Professor Freda Miller`s findings discovered at McGill University`s Montreal Neurological Institute, Aegera`s academic collaborator, indicate that adult skin is a source of multipotent stem cells which can be directed toward neuronal or mesodermal development, including neurons, glia, smooth muscle cells and adipocytes.
Quoting from Dr. Miller`s article, "These findings indicate that adult tissues contain tissue-biased stem cells,... that may be much more `plastic` than previously appreciated... the ability to readily isolate and expand such a stem cell, from an accessible potentially autologous source such as human skin, has important therapeutic implications."
Curis, Inc. and Aegera Therapeutics Inc. entered into a licensing and research agreement in January 2001, under which Aegera granted to Curis an exclusive worldwide license on Aegera`s skin-derived, adult stem cell technologies. The agreement established a broad collaboration to investigate the therapeutic potential of these technologies in neurological, pancreatic and cardiovascular disorders. Research is to be conducted at Curis, Aegera, and McGill University`s Montreal Neurological Institute.
Doros Platika, M.D., president and chief executive officer of Curis states, "We are delighted to see confirmation of our hypothesis that stem cells present in adult skin may be able to give rise to a variety of cell types that go beyond their tissue of origin. Combining Curis` expertise in stem cells, growth factors and small molecules, with Aegera`s technology, may allow the treatment of various diseases using stem cells derived from a very accessible adult source. This will also avoid any ethical concerns surrounding the use of embryonic stem cells. The focus of our collaboration is in the field of Diabetes, Neurology and Cardiovascular medicine."
Mr. Michael Atkin, Aegera`s president commented, "Dr. Freda Miller`s dramatic proof of principle for generation of multipotent stem cells from adult skin offers hope of providing a safe, non-invasive and ethically appealing source of stem cells that our society can broadly welcome. I congratulate Dr. Miller and her team on their vision and commitment, which I believe to be equalled by our partners at Curis."
About Curis, Inc.
Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. The Company is combining insights gained through the study of developmental biology with high-throughput screening capabilities, proteins, cells and biocompatible materials to facilitate the development of new regenerative medicine therapies. For more information, please visit the Curis web site and view our webcast productions on Monday, August 13, 2001, at www.curis.com.
About Aegera Therapeutics, Inc.
Aegera Therapeutics Inc. is a privately-held biotechnology company headquartered in Montreal, Canada. In addition to the Company`s stem cell focus, Aegera is developing small molecule drugs to treat central and peripheral nerve diseases, and in cancer to restore normal cell-death mechanisms by inducing apoptosis. For more information, please visit the Aegera web site at www.aegera.com.
The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, regulatory approval and commercialization, the impact of competitive products, patents, patent litigation, product liability, third party reimbursement, and other risks and uncertainties associated with the biotechnology industry. For additional factors that could cause actual results to differ materially, please refer to the risk factors section of the Curis Annual Report on Form 10-k for the year ended December 31,2000 with the Securities and Exchange Commission on March 30, 2001
Hallo zusammen!
Wie ist eure derzeitige Einschätzung zu Curis, unter langfristigen Gesichtspunkten von mehreren Jahren?
Ich habe mich zwar schon auf der Webseite von Curis umgesehen, ich würde mich jedoch freuen, wenn jemand nochmal die Produktpipeline von Curis nennen und erläutern könnte. Wenn ich nicht irre ist diese doch recht ordentlich, mit mehreren Wirkstoffen in den Testphasen eins bis drei und auch in den vorklinischen Testphasen.
Danke und Gruß, greenhorn
Wie ist eure derzeitige Einschätzung zu Curis, unter langfristigen Gesichtspunkten von mehreren Jahren?
Ich habe mich zwar schon auf der Webseite von Curis umgesehen, ich würde mich jedoch freuen, wenn jemand nochmal die Produktpipeline von Curis nennen und erläutern könnte. Wenn ich nicht irre ist diese doch recht ordentlich, mit mehreren Wirkstoffen in den Testphasen eins bis drei und auch in den vorklinischen Testphasen.
Danke und Gruß, greenhorn
Guten Abend!
Wie ich sehe, ist es doch eher ruhig um Curis geworden. Vielleicht kommt die Diskussion ja bald wieder in Gang. Unter langfristigen Gesichtspunkten kann man auf diesem Niveau sicherlich wenig falsch machen, wenn man sich ein paar Stücke ins Depot legt. Eure Meinung?
Gruß, grenhorn
Wie ich sehe, ist es doch eher ruhig um Curis geworden. Vielleicht kommt die Diskussion ja bald wieder in Gang. Unter langfristigen Gesichtspunkten kann man auf diesem Niveau sicherlich wenig falsch machen, wenn man sich ein paar Stücke ins Depot legt. Eure Meinung?
Gruß, grenhorn
Absolut richtig. Die Aktie ist krass unterbewertet (siehe oben). Curis könnte zu den großen Gewinnern gehören, wenn der Markt sich dreht. Die Frage ist nur: Wann wird das sein?
Ist ja wieder heftig abgeprallt von 1,20
Hoffentlich der letzte tiefe Atemzug vor dem Ausbruch.
Hoffentlich der letzte tiefe Atemzug vor dem Ausbruch.
So,das lange Warten hat sich endlich gelohnt.
Heute fast 100% im Plus. Suuuuppper
Heute fast 100% im Plus. Suuuuppper
EquityOutlook.Com: EquityOutlook.Com announces Stock Evaluation Ratings for Curis Inc, Lowe`s, Providian, Wachovia Corp, BJ Services Company
via COMTEX
May 7, 2003
SHREVEPORT, La., May 07, 2003 (M2 PRESSWIRE via COMTEX) --
EquityOutlook.Com makes these short-term stock recommendations:
Curis Inc (NASDAQ:CRIS - News) - BUY Lowe`s (NYSE:LOW - News) - SELL Providian (NYSE:PVN - News) - WEAK BUY Wachovia Corp (NYSE:WB - News) - WEAK BUY BJ Services Company (NYSE:BJS - News) - BUY
WHAT THESE RATINGS MEAN: EquityOutlook.Com ranks stocks with a proprietary unbiased system of technical analysis. These ratings do not indicate a `long term`view of any company listed. These are ratings that reflect our opinion of a stock`s potential price movement over the next five to ten trading sessions. The stock ratings range from +10 (which indicates our view that a stock has a great chance to move higher) to - 10 (which indicates our belief that a stock has a great chance to move lower).
These ratings may change based on daily market conditions.
ABOUT EquityOutlook.Com: EquityOutlook.Com is a stock research firm. Our daily commentary has regular, worldwide distribution. We are Registered Investment Advisors. We do not accept third-party compensation to make stock suggestions. We do not own shares of any stock we rate.
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. Reproduction without written permission is prohibited.
EquityOutlook.Com`s goal is to provide stock research FREE from bias or conflicts. You can get your FREE trial to EquityOutlook.Com at http://www.equityoutlook.com.
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
(C)1994-2003 M2 COMMUNICATIONS LTD
JS200
via COMTEX
May 7, 2003
SHREVEPORT, La., May 07, 2003 (M2 PRESSWIRE via COMTEX) --
EquityOutlook.Com makes these short-term stock recommendations:
Curis Inc (NASDAQ:CRIS - News) - BUY Lowe`s (NYSE:LOW - News) - SELL Providian (NYSE:PVN - News) - WEAK BUY Wachovia Corp (NYSE:WB - News) - WEAK BUY BJ Services Company (NYSE:BJS - News) - BUY
WHAT THESE RATINGS MEAN: EquityOutlook.Com ranks stocks with a proprietary unbiased system of technical analysis. These ratings do not indicate a `long term`view of any company listed. These are ratings that reflect our opinion of a stock`s potential price movement over the next five to ten trading sessions. The stock ratings range from +10 (which indicates our view that a stock has a great chance to move higher) to - 10 (which indicates our belief that a stock has a great chance to move lower).
These ratings may change based on daily market conditions.
ABOUT EquityOutlook.Com: EquityOutlook.Com is a stock research firm. Our daily commentary has regular, worldwide distribution. We are Registered Investment Advisors. We do not accept third-party compensation to make stock suggestions. We do not own shares of any stock we rate.
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. Reproduction without written permission is prohibited.
EquityOutlook.Com`s goal is to provide stock research FREE from bias or conflicts. You can get your FREE trial to EquityOutlook.Com at http://www.equityoutlook.com.
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
(C)1994-2003 M2 COMMUNICATIONS LTD
JS200
Was isn das für ein Boersendienst. Hab vor einer Woche auch bei Freerealtime.com unter News bei Curis die Meldung von equityoutlook.com gesehen, da stand aber noch CURIS - Sell! Und nun ein paar Tage später auf einmal BUY. Was ist das für ein Schrott-Dienst????
Bios laufen wieder gut.
Curis ist eine Turnarround <Aktie ,da bin ich mir sicher.
Wenn die 3 Dollars fallen,sollte es weiter gehen.
Curis ist eine Turnarround <Aktie ,da bin ich mir sicher.
Wenn die 3 Dollars fallen,sollte es weiter gehen.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -0,02 | |
| +10,17 | |
| +0,01 | |
| +0,04 | |
| +0,10 | |
| -0,11 | |
| +0,77 | |
| -0,35 | |
| 0,00 | |
| -0,10 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 296 | ||
| 141 | ||
| 103 | ||
| 93 | ||
| 72 | ||
| 68 | ||
| 55 | ||
| 47 | ||
| 46 | ||
| 46 |
